SGLT2 inhibitor empagliflozin alleviates cardiac remodeling and contractile anomalies in a FUNDC1-dependent manner in experimental Parkinson’s disease

Wei Yu(University of Kansas Medical Center), Jun Ren(Fudan University)
Acta Pharmacologica Sinica
September 7, 2023
Cited by 30


Related Papers